Anti-Human CD44 Recombinant Antibody (RG7356) (CAT#: TAB-128CL)
Recombinant Humanized monoclonal antibody expressed in CHO binding to Human CD44. RG7356 is a humanized antibody targeting the constant region of CD44 that shows antitumor efficacy in mice implanted with CD44-expressing tumors such as MDA-MB-231 breast cancer cells. Short-term treatment of tumor-bearing mice with RG7356 resulted in modifications of the MAPK pathway in the responsive model, although no effects on downstream phosphorylation were observed in a nonresponsive xenograft model.
Specific Inquiry
Figure 1 RG7356 serum concentration versus time plot in patients in Arm A who received the biweekly (q2w) (A) and weekly (qw) (B) dosing schedules.
Menke-van der Houven, C. W., van Oordt, C. G. R., van Herpen, C., Coveler, A. L., Mahalingam, D., Verheul, H. M.,... & Cannarile, M. A. (2016). First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. Oncotarget, 7(48), 80046.
Specifications
- Derivation
- Humanized
- Type
- Antibody
- Species Reactivity
- Human
- Related Disease
- Chronic Lymphocytic Leukemia; Solid Tumors
Product Property
- Purity
- >98% by SDS-PAGE and HPLC analysis
- Storage
- 4°C or -20°C, avoid repeated freezing and thawing.
Target
- Alternative Names
- CD44; CD44 molecule (Indian blood group); IN; LHR; MC56; MDU2; MDU3; MIC4; Pgp1; CDW44; CSPG8; HCELL; HUTCH-I; ECMR-III; CD44 antigen; epican; Hermes antigen; hyaluronate receptor; phagocytic glycoprotein 1; heparan sulfate proteoglycan; cell surface glyc
- Gene ID
- 960
- UniProt ID
- P16070
Related Resources
Solier, Stéphanie, et al. "A druggable copper-signalling pathway that drives inflammation." Nature 617.7960 (2023): 386-394.
This study focuses on the role of CD44-mediated copper uptake in regulating inflammation through metabolic and epigenetic reprogramming in macrophages. The researchers found that CD44 facilitates the uptake of copper(II) in mitochondria, which catalyzes NAD(H) redox cycling, promoting metabolic changes and subsequent epigenetic modifications that lead to an inflammatory state. They developed a metformin dimer, LCC-12, which inactivates mitochondrial copper(II), thereby inducing metabolic and epigenetic shifts that counteract macrophage activation. This study highlights the potential of targeting mitochondrial copper(II) as a therapeutic strategy to reduce inflammation in various disease models, including bacterial and viral infections.
Creative Biolabs contributed significantly to this research by providing the Anti-CD44 antibody (Cat# TAB-128CL). This antibody was crucial for the experiments involving the detection and analysis of CD44-mediated copper uptake in macrophages. The precise measurement and modulation of CD44 activity facilitated a deeper understanding of the mechanisms by which CD44 regulates macrophage metabolism and inflammation, thus supporting the study's exploration of new therapeutic approaches based on metabolic reprogramming.
Gomez, Karina E., et al. "Cancer cell CD44 mediates macrophage/monocyte-driven regulation of head and neck cancer stem cells." Cancer research 80.19 (2020): 4185-4198.
This study explores the interaction between tumor-associated macrophages (TAMs) and cancer stem cells (CSCs) in head and neck squamous cell carcinoma (HNSCC), focusing on the role of the CD44 receptor. The researchers found that TAMs enhance the stemness and invasive properties of CSCs by modulating CD44 signaling pathways, particularly through the PI3K-4EBP1-SOX2 axis. Using patient-derived samples, in vitro coculture spheroid models, and in vivo mouse models, the study demonstrated that TAMs increase the availability of hyaluronic acid (HA), which binds to CD44 and activates signaling pathways that promote CSC growth and invasion. This mechanistic link between TAMs and CSCs provides insights into potential therapeutic targets for HNSCC.
Creative Biolabs provided essential reagents for this study, specifically the anti-CD44 monoclonal antibody (Cat# TAB-128CL). This antibody was crucial for the experiments involving CD44 detection and functional analysis in cancer cells. By enabling precise measurement and modulation of CD44 activity, the antibody facilitated a deeper understanding of how CD44 mediates the interaction between TAMs and CSCs. The use of Creative Biolabs' high-quality reagents significantly advanced the study's investigation into the molecular mechanisms underlying CSC regulation by TAMs.
More Infomation
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "CD44"
Select a product category from the dropdown menu below to view related products.
Please select product type
Fab Fragment Antibody
Humanized Antibody
Mouse Antibody
Human Antibody
Chimeric Antibody
Recombinant Antibody
Chicken IgY Antibody
Blocking Antibody
Neutralizing Antibody
Rabbit Monoclonal Antibody
scFv Fragment Antibody
ADCC Enhanced Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| DrMAB-991 | Mouse Anti-CD44 Recombinant Antibody (clone BU52) | IHC, WB, IP, Inhib, Stim | Mouse IgG1 F(ab')2, κ |
| HPAB-0154-FY-F(E) | Human Anti-CD44 Recombinant Antibody (clone (hu)ARH460-16-2 variant HV2/KV1); Fab Fragment | Inhib | Humanized Fab |
| HPAB-1055-FY-S(P) | Mouse Anti-CD44 Recombinant Antibody; scFv Fragment (HPAB-1055-FY-S(P)) | IHC, Inhib, FC | Mouse scFv |
| HPAB-1056-FY-S(P) | Mouse Anti-CD44 Recombinant Antibody; scFv Fragment (HPAB-1056-FY-S(P)) | IHC, Inhib, FC | Mouse scFv |
| HPAB-0443-YJ-F(E) | Human Anti-CD44 Recombinant Antibody (clone CA14); Fab Fragment | ELISA, FuncS | Human Fab |
Customer Reviews and Q&As
Customer Review
Q&As
-
Ideal for Therapeutic Studies
The Anti-CD44 Therapeutic Antibody (RG7356) has been a fantastic addition to our therapeutic research. Its specificity and sensitivity are outstanding, consistently providing clear results. This antibody has become essential for our studies, improving the accuracy and reliability of our assays. -
Great for Immunoassays
We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for CD44 is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab. -
Consistent and Effective
This antibody has proven to be consistent and effective in our various assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for CD44 have been particularly beneficial.
Popular products with customers
Application: WB, FuncS, IF, Neut, ELISA, FC, IP
Application: FC, IP, ELISA, Neut, FuncS, IF, ICC
Application: ELISA, IP, FC, FuncS, Neut, IF, WB
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: WB, ELISA, FC, IP, FuncS, IF, Neut
Application: WB, IF, IP, Neut, FuncS, ELISA, FC
Application: FC, IP, ELISA, Neut, FuncS, IF, ICC
Application: WB, FuncS, IF, Neut, ELISA, FC, IP
Application: IP, IF, FuncS, FC, Neut, ELISA, IHC
Application: Neut, Inhib, FC, ELISA
Application: FC, IA, IF, IP, IHC, FuncS
Application: Inhib, ELISA, FC, FuncS
Application: IF, IP, Neut, FuncS, ELISA, FC
Application: ELISA, FuncS
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
